CH de Frejus
Fréjus, France
NCT Number: NCT03859518
The cohort included only major patients with non-segmental vitiligo and no other autoimmune or inflammatory associated diseases (except thyroiditis). Control subjects should have no autoimmune or inflammatory diseases. Patients and controls should not take treatment with corticosteroids or other potentially immunomodulatory therapies. Patients and controls are recruited in the Dermatology Department of the University Hospital of Nice and the Hospital of Fréjus. The investigators have already initiated the collection of tissues and blood from patients and control subjects and we have succeeded in isolating ILCs and NKs from a blood volume of 50ml. We were able to sort the ILC subpopulations. Early data suggest an increase in Natural Killer (NK) and Innate Lymphoïdes Cells 1 (ILC1) in the blood of vitiligo patients compared to control subjects. The investigators also managed to extract the melanocytes from the skin biopsies of the first patients and control subjects.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Fréjus, France
The investigators want study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
vitiligo subjects :
control subjects :
To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
Time frame: 1 day
Compare vitiligo patients to control subjects.
Time frame: 1 day
Compare vitiligo patients to control subjects.
Centre Hospitalier Universitaire de Nice
Other
Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo
Acronym: INNATEvitiligo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00696358
Hypopigmentation, Pigmentation Disorders
Nice, France
View Trial DetailsNCT04822584
Hypopigmentation, Pigmentation Disorders
Bordeaux, France
View Trial DetailsNCT07181187
Hypopigmentation, Pigmentation Disorders
Hangzhou, Zhejiang, China
View Trial DetailsNCT04237103
Hypopigmentation, Pigmentation Disorders
Bordeaux, France
View Trial Details